Allure has written up a new Nature Health study that ran an AI analysis of 400,000 Reddit posts shared over more than five years by people taking GLP-1 medications. The symptoms that surfaced were not the ones on the label.

The drugs involved are semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro and Zepbound), both widely used for obesity and type 2 diabetes. Researchers found posts from 67,008 users describing the familiar complaints, nausea, vomiting, constipation and diarrhea, alongside a second cluster: fatigue, menstrual irregularities, chills and hot flashes.

Why social posts, not trials

This is the rare case where mining a forum is doing something a trial cannot. The authors wrote that the findings "highlight patient concerns not well captured in current labelling or trials," which is a polite way of saying the label was built from data that never asked these questions.

The study did not conclusively prove that GLP-1s caused any of these symptoms, and Allure says so plainly. It established a link, and some of the symptoms may be attributable to weight loss rather than the drugs.

The hormone confounder

Mir Ali, MD, of MemorialCare Surgical Weight Loss Center, told Allure that many changes during significant weight loss are tied to hormones: estrogen levels typically drop in women who lose substantial weight, while testosterone tends to rise in men. Patients on these medications can lose up to 20 percent of body weight over 72 weeks, which is enough to move a lot of things at once.

Kelley Gregorovic, MS, a family nurse practitioner at Tufts Medicine Weight and Wellness Center, said menstrual changes "make the most sense to me clinically," citing recent analyses of FDA adverse event reports. She also noted that a woman starting a GLP-1 in midlife may be seeing weight, metabolic health and hormones shift simultaneously, which makes attribution genuinely hard.

Where the clinicians are skeptical

Hot flashes and chills got the coolest reception. Gregorovic said she is "more cautious" about linking those to the drugs, Ali called it an uncommon complaint, and Rutuja Patel, DO, of Northwestern Medicine said these particular side effects "are not very common."

A label written before the data

The useful finding here is not a new side effect. It is evidence that what patients report and what the paperwork lists have drifted apart, and that the gap is worth studying.